Hoeppner Jens
Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Chirurg. 2021 Dec;92(12):1094-1099. doi: 10.1007/s00104-021-01475-w. Epub 2021 Aug 13.
Locally advanced esophageal cancer is mostly treated in multimodal therapy protocols according to the current western treatment guidelines. In squamous cell cancer, neoadjuvant chemoradiotherapy is in the foreground. Unimodal surgical and chemoradiation treatment alternatives achieve poorer results for this entity. Surgical salvage resection for tumor recurrence after definitive chemoradiotherapy can be carried out with good oncological results but the frequency of postoperative complications is increased. For locally advanced adenocarcinoma of the esophagus, perioperative chemotherapy and neoadjuvant chemoradiotherapy are two competing level 1 evidence-based treatment concepts that are superior to treatment by surgery alone. The results of head-to-head comparative treatment studies are still pending. A significant number of patients show a complete locoregional remission of the tumor in the surgical specimen after treatment with the modern neoadjuvant protocols. Currently, European prospective randomized noninferiority studies with an oncological endpoint are testing the possibilities of organ-retaining concepts in clinical complete remission (surgery as needed; watch and wait). For the future, it is to be expected that the curative treatment results of locally advanced esophageal carcinoma will again significantly improve, in particular through the additional possibilities of immunotherapy and organ-preserving therapy concepts for postneoadjuvant complete remission.
根据当前西方治疗指南,局部晚期食管癌大多采用多模式治疗方案。在鳞状细胞癌中,新辅助放化疗处于前沿。对于该类型癌症,单一的手术和放化疗替代方案效果较差。根治性放化疗后肿瘤复发的手术挽救性切除可以取得良好的肿瘤学效果,但术后并发症的发生率会增加。对于局部晚期食管腺癌,围手术期化疗和新辅助放化疗是两种相互竞争的1级循证治疗理念,均优于单纯手术治疗。头对头比较治疗研究的结果仍未可知。相当数量的患者在接受现代新辅助方案治疗后,手术标本中的肿瘤出现完全局部区域缓解。目前,欧洲以肿瘤学为终点的前瞻性随机非劣效性研究正在测试临床完全缓解时保留器官理念的可能性(按需手术;观察等待)。展望未来,预计局部晚期食管癌的根治性治疗效果将再次显著改善,特别是通过免疫治疗以及新辅助后完全缓解时保留器官治疗理念带来的更多可能性。